G.N. Ismailova

https://orcid.org/0000-0002-7461-4190

Articles found: 3

  • Combined surgery of lung echinococcosis (Issue № 4, 2024)

    B.K. Shirtayev, S.A. Kaniyev, G.N. Ismailova, N.Zh. Yerimova, D.R. Kurbanov, M.G. Aitzhanov, N.N. Rakhman
    2024-12-31
    25–33
    Abstract

    Background. Pulmonary cystic echinococosis, a parasitic disease, is a health care problem in developing countries. In this study, we evaluated outcomes of patients with pulmonary hydatid disease who were treated in our department.Study was performed to compare results of surgical treatment and complications of patients with unilateral or bilateral thoracic and combined pulmonary cystic echinococosis.

    Methods. This cross-sectional analysis of a prospective study was conducted in the Department of Thoracic and Pediatric Surgery, Scientific Center of Surgery, Almaty, Kazakhstan among 598 patients with pulmonary cystic echinococosis, who had surgical treatment with various surgical methods, depending on the prevalence of echinococcosis, as follows: right lung in 357 (59.5%) patients, left lung in 243 (40.5%) patients, bilateral in 95 (15.8%) patients, and complicated echinococcosis in 317 (52.8%) patients. Length of stay per hospital stay has been decreased (p 0.0001) by video-thoracoscopicechinococcectomy with the high-energy laser treatment of cyst, than after echinococcectomy by cyst treatment with povidone-iodine. Treatment with formalin presented the longest hospital stay (p 0.0001).

    Results. Comparative analysis of patients with uncomplicated and complicated pulmonary cystic echinococosis showed a high frequency of postoperative complications associated with complicated echinococcosis (OR = 2.2, p 0.0001).

    Conclusion. Despite the success of surgical treatment of pulmonary cystic echinococosis, issues of intraoperative dissemination and safety remain, and treatment success rates can be improved. These factors require further prospective multicenter studies.

    Keywords

    pulmonary cystic echinococosis, video- assisted thorascopicechinococcectomy, bilateral echinococcosis, transmedistinal access, combined echinococcosis

  • WHAT SCALES SHOULD THE CARDIOLOGIST USE IN PATIENTS WITH ATRIAL FIBRILLATION? WHAT IS NEW? (Issue № 2, 2024)

    K.A. Bizhanov, A.K. Baimbetov, B.B. Baimakhanov, Sh.A. Kaniev, O.T. Ibekenov, A.B. Sarsenbaeva, G.N. Ismailova
    2024-06-28
    61–77
    Abstract

    The current treatment algorithm for patients with non-valvular atrial fibrillation (AF) includes anticoagulation to prevent stroke and systemic embolism, improvement of AF symptom control by heart rate reduction or restoration and maintenance of sinus rhythm, and treatment of cardiovascular and other comorbidities. The evaluation of patients with AF should be structured and include assessment of stroke risk, symptom severity, severity of the AF burden (type of arrhythmia, number and duration of episodes, etc.) and predisposing condition. The use of the CHA2DS2-VASc (risk of stroke), HAS-BLED (risk of bleeding), EHRA (severity of AF symptoms), and 2MACE (risk of cardiovascular outcomes) scales is important to help assess the likelihood of adverse outcomes and select the optimal treatment to protect not only against stroke but also against cardiovascular events. It should be noted that the HAS-BLED scale is primarily necessary for identification of bleeding risk factors, the modification of which allows to increase the safety of anticoagulant therapy, and a high index value according to this scale can’t serve as a reason to refuse anticoagulation in a patient with AF. New scales of stroke and hemorrhagic complications risk assessment in patients with AF on the basis of clinical parameters and laboratory biomarkers have been proposed, but their possible advantages over the existing indices need to be confirmed in special studies.

    Keywords

    Atrial fibrillation, stroke, bleeding, scales, direct oral anyicoagulants, myocardial infarction, interventional arrhythmology, cardiology

  • Combined treatment of digeorge syndrome (Issue № 1, 2024)

    G.N. Ismailova, A.K. Khamidulla, I.A. Yakupova, I. Omarkyzy, A.D. Temirkhanov
    2024-05-21
    38–45
    Abstract

    Background. DiGeorge syndrome is a rare congenital disease associated with a deletion of chromosome 22q11.2, which is characterized by the occurrence of various anomalies, such as hypo/aplasia of the thymus and parathyroid glands, which leads to T-cell immunodeficiency and hypoparathyroidism; this syndrome is also characterized by congenital heart disease (tetralogy of Fallot), anomalies in the development of craniofacial structures are observed, in the form of non-fusion of the hard palate and upper lip (cleft palate and cleft lip).

    Results. This article will examine a clinical case of DiGeorge syndrome in a child, with the classic triad characteristic of this condition (immunodeficiency, hypoparathyroidism and congenital heart disease). The patient underwent the first stage of correction of a combined heart defect against the background of constant (monthly) immunocorrection. Due to the COVID-19 pandemic, our patient was unable to receive scheduled hospitalization for blood replacement and immunocorrective therapy in a timely manner. The key to increasing the survival rate of patients with DiGeorge syndrome is prenatal screening, timely correction of the anomaly and immunoreplacement therapy, which are actively used in foreign countries. Also, incomplete treatment of DiGeorge syndrome can subsequently lead to various other manifestations, such as autoimmune diseases, infectious diseases, etc.

    Conclusion. The prognosis of DiGeorge syndrome is that this disease has various clinical manifestations, is combined with other variants of the anomaly that are incompatible with life and lead to delayed psychomotor development and have an unfavorable prognosis.

    Keywords

    DiGeorge syndrome, thymic hypo/aplasia, tetralogy of Fallot, thymus transplantation